Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Study could clarify CTC-based staging of metastatic breast cancer

Davis A et al. ASCO 2018 Poster 1019.

Key clinical point: A CTC count less than 5 per 7.5 mL of blood in patients with MBC indicates an indolent disease subset.

Major finding: Median OS for stage IVindolent vs. stage IVaggressive disease was 4.0 vs. 17.3 months in HER2-negative patients, 23.8 vs. 9.0 months in TNBC patients, and 36.7 vs. 20.4 months in HER2-positive disease.

Study details: A pooled analysis of data from two cohort studies including 2,436 patients.

Disclosures: This study was supported by the Lynn Sage Breast Cancer Research OncoSET Program at Robert H. Lurie Cancer Center. Dr. Davis reported having no disclosures.

Read the article.


Davis A et al. ASCO 2018 Poster 1019.

This Week's Must Reads

PFS superior with avelumab and axitinib in advanced RCC, Motzer RJ et al. ESMO 2018. Abstract LBA6_PR

Adjuvant axitinib may benefit highest risk RCC patients, Quinn DI et al. Ann Oncol. 2018 Oct 20. doi: 10.1093/annonc/mdy454

High KPNA2 signals poor outcomes for RCC, Kristiansen G et al. Clin Genitourin Cancer. 2018 Oct 22. doi: 10.1016/j.clgc.2018.10.008

RCC patient and disease characteristics differ by race/ethnicity, Batai K et al. Clin Genitourin Cancer. 2018 Oct 26. doi: 10.1016/j.clgc.2018.10.012

Change in tumor burden signals treatment needs in mRCC, Bimbatti D et al. Urol Oncol. 2018 Oct 6. doi: 10.1016/j.urolonc.2018.08.018

Must Reads in Breast Cancer

Avoiding topical agents prior to RT may be unnecessary, Baumann BC et al. JAMA Oncol. 2018 Oct 18. doi: 10.1001/jamaoncol.2018.4292

Men with MBC have a similar prognosis compared with women, Sirieix et al. ESMO 2018, Abstract 294PD; Reinisch et al. ESMO 2018, Abstract 273PD

Inherited mutations account for 12% of Nigerian breast cancer, Olopade et al. J Clin Oncol. 2018 Aug 21. doi: 10.1200/JCO.2018.78.3977.